Investors

Press Releases

All Releases

View Summary Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
May 2, 2016
PDF 15.6 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2016 Investor Conference Presentations
Apr 29, 2016
PDF 10.3 KB Add to Briefcase
View Summary Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Apr 15, 2016
PDF 8.5 KB Add to Briefcase
  Regeneron Hires Sally A. Paull as Senior Vice President, Human Resources
Apr 13, 2016
PDF 72.9 KB Add to Briefcase
View Summary Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Apr 11, 2016
PDF 13.9 KB Add to Briefcase
  Regeneron and MedImmune Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer
Apr 5, 2016
PDF 269.2 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Apr 1, 2016
PDF 22.9 KB Add to Briefcase
  Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Trial Data at ACC.16
Mar 30, 2016
PDF 196.9 KB Add to Briefcase
View Summary Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Mar 24, 2016
PDF 14.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Mar 23, 2016
PDF 21.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal
Mar 16, 2016
PDF 20.5 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Mar 11, 2016
PDF 20.1 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Humana Provides Exclusive or Preferred Access to Praluent® (alirocumab) Injection on their Commercial and Medicare Formularies
Mar 4, 2016
PDF 17.2 KB Add to Briefcase
View Summary Regeneron Genetics Center Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
Mar 2, 2016
PDF 15.9 KB Add to Briefcase
  Regeneron Hires David Weinreich, M.D., M.B.A., as Senior Vice President, Late Stage Clinical Development and Medical Affairs
Mar 1, 2016
PDF 97.0 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2016 Investor Conference Presentation
Feb 29, 2016
PDF 9.9 KB Add to Briefcase
View Summary Regeneron Joins Human Vaccines Project to Improve Global Disease Prevention and Treatment
Feb 10, 2016
PDF 12.7 KB Add to Briefcase
View Summary Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
Feb 9, 2016
PDF 55.0 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2016 Investor Conference Presentation
Feb 2, 2016
PDF 9.9 KB Add to Briefcase
  Regeneron and Sanofi Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association
Feb 2, 2016
PDF 66.3 KB Add to Briefcase
Showing 1-20 of 328 Page: 1 2 3 4 5 ... 17  Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)